



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

15 April 2026  
EMA/70065/2026  
Regulatory Science and Innovation Task Force

## Agenda — Medicine Shortages SPOC Working Party

Wednesday, 15 April 2026, from 09:30 to 13:40 (CEST), TEAMS

**Chair: Monica Dias (EMA), Stand-in Vice-Chair: Mathilde Moe Møldrup (DKMA, Denmark)**

Item	Topic
1.	Welcome, declaration of interest, adoption of draft agenda
2.	Adoption of draft minutes of the SPOC WP meeting held on 16-17 March 2026
3.	<b>Potential impact of the international situation</b> on the supply of medicinal products for human and veterinary use to the European market:
	Feedback from the SPOC WP subgroup on crisis monitoring and preparedness <ul style="list-style-type: none"><li>• Update on the geopolitical situation</li></ul>
4.	Oral status update on availability of human and veterinary medicines in MSs (only for new emerging information)

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



Item	Topic
5.	<b>Critical shortages escalated to the SPOC Working Party:</b>
5.1	<b>Ongoing shortages</b>
	a) Ifosfamide containing medicinal products and cyclophosphamide containing medicinal products, MAH: Baxter
	b) Medicinal products affected by fire incident at Viatris manufacturing site
	c) Gastrografin NAP and Urografin NAP (sodium amidotrizoate, meglumine amidotrizoate), MAH: Bayer
	d) Praziquantel containing medicinal products
	e) Nexobrid CAP (concentrate of proteolytic enzymes enriched in bromelain), MAH: MediWound Germany GmbH
5.2	<b>Status update on other critical shortages escalated to the SPOC WP</b> (only comments relating to previously circulated written updates)
	a) NovoSeven CAP (eptacog alfa), MAH: Novo Nordisk
	b) Medicinal products containing salbutamol (inhalation use)
	c) Medicinal products from MAH Cheplapharm
6.	Impact of nitrosamines impurities on the availability of medicines
7.	EC DG SANTE update
8.	Executive Steering Group on Shortages and Safety of Medicinal Products ( <b>MSSG</b> )-led activities:
	a) Feedback from the MSSG meeting on 23 March 2026
	b) Feedback from the MSSG WG on Vulnerability Assessment Methodology
	c) Union list of Critical Medicines and Union long list update
9.	Medicine Shortages Communication (MSC) pilot
10.	ESMP update

Item	Topic
11.	AOB
12.	Conclusions and next steps

---

**Next meeting:** 12 May 2026, TEAMS

---